Glaxo (GSK) Hoping for More Gene-Research Loot

Now that GlaxoSmithKline (NYSE:GSK) has had its first success with Human Genome Sciences (NASDAQ:HGSI), they are hoping they'll be able to expand their offerings beyond the lupus drug, Benlysta, which was approved for use by the U.S. Food and Drug Administration.

Other drug studies being carried out by the partnership are in relationship to heart disease and diabetes.

In those categories they're still several years away from being marketed, and still must navigate successfully through the testing process before being considered for approval or not.

What's important for Glaxo and Human Genome is the understanding that there is an important part the mapping of the human genome can have on successful treatments.

Human Genome closed Thursday at $29.03, gaining $3.35, or 13.05 percent. Glaxo closed at $38.40, dropping $0.18, or 0.47 percent.